Trade URGN anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
UroGen Pharma Ltd. (URGN) is trading at US$43.96, down 3.40% today as of Aug 28, 12:15 EDT. The company has a market capitalisation of US$2.29B. Over the past 52 weeks, URGN has traded between US$15.86 and US$50.81. On Syfe you can trade URGN with $0 commission and add it to your watchlist.
| Previous close | US$45.50 |
|---|---|
| Market cap | US$2.29B |
| P/E ratio | 27.88 |
| 52-week range | US$15.86 – US$50.81 |
| Volume | 559.77K |
| Exchange | US |
Add to Watchlist
Set Price Alert
UroGen Pharma Ltd.
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
Year: 2017
UroGen Pharma Ltd. (URGN) stock is trading at US$43.96, -3.40% from the previous close of US$45.50.
The market cap for UroGen Pharma Ltd. (URGN) stock is approximately US$2.29B.
The price-to-earnings ratio for UroGen Pharma Ltd. (URGN) is 27.88, based on the latest reported earnings.
The 52-week high for UroGen Pharma Ltd. (URGN) stock is US$50.81.
The 52-week low for UroGen Pharma Ltd. (URGN) stock is US$15.86.
UroGen Pharma Ltd. (URGN) does not currently pay a dividend.
Stay on top of URGN
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
